Skip to main content
SpringerLink
Log in

The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease

  • Short communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

This double-blind, randomized parallel group study investigated the effect of 6 months β-adrenoceptor antagonist therapy with either metoprolol (β1-selective without intrinsic sympathomimetic activity [ISA]) or epanolol (β1-selective with ISA) on markers of endogenous fibrinolysis in 20 patients with chronic stable angina receiving concurrent treatment with nifedipine.

Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1). A significant correlation between fasting insulin and PAI-1 has previously been described and was confirmed in this study. The group treated with metoprolol showed a significant rise in fasting insulin after 6 months with no change in PAI-1.

This suggests that the previously described link between these two may not be causal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH (1993) Endogenous tissue-type plasminogen activator and risk of mayocardial infarction. Lancet 341: 1165–1168

    Google Scholar 

  2. Jansson JH, Nilsson TK, Olofsson BO (1991) Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12: 157–161

    Google Scholar 

  3. Hamsten A, Wiman B, De Faire U, Blomback M (1985) Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–1563

    Google Scholar 

  4. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet II: 3–9

    Google Scholar 

  5. Norwegian multicenter group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807

    Google Scholar 

  6. Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G (1991) Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease; potential effects of β-blockade. Circulation 84 [Suppl 6]: 72–77

    Google Scholar 

  7. Smith HJ, Halliday SE, Earl DCN, Stribling D (1983) Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292. J Pharmac Exp Ther 226: 211–216

    Google Scholar 

  8. MacGregor IR, MacDonald S, Dawes J, Micklem LR, James K (1987) A monoclonal antibody enzyme linked immunosorbent assay directed towards a fibrin binding region of tissue-type plasminogen activator. Fibrinolysis 1: 247–252

    Google Scholar 

  9. Booth NA, Simpson AJ, Croll A, Bennet B, MacGregor IR (1988) Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70: 327–333

    Google Scholar 

  10. Soeldner JS, Slone D (1965) Critical variables in the radioimmunoassay of serum insulin using the double antibody technic. Diabetes 14: 771–779

    Google Scholar 

  11. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D (1989) Plasma plasminogen activator inhibitor-1 in angina pectoris; influence of plasma insulin and aute-phase response. Arterioslerosis 9: 362–367

    Google Scholar 

  12. Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157

    Google Scholar 

  13. Roberts WC (1989) Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 117: 709–714

    Google Scholar 

  14. Jurgensen HJ, Dalsgaard-Nielsen J, Kjoller E, Gormsen J (1981) Effect of long-term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease. Eur J Clin Pharmacol 20: 245–250

    Google Scholar 

  15. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P (1990) Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 63: 482–487

    Google Scholar 

  16. Teger-Nilsson AC, Dahlof C, Haglund E, Hedman C, Olsson G, Ablad B (1990) Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study. J Clin Pharmacol 30 [Suppl]: s132-s137

    Google Scholar 

  17. Jimenez AH, Tofler GH, Chen X, Stubbs ME, Solomon HS, Muller JE (1993) Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension. Am J Cardiol 72: 47–52

    Google Scholar 

  18. De Boer A, Kluft C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, Soons PA, Cohen AF (1993) Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects. Br J Clin Pharmac 36: 99–104

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Research Unit, University of Edinburgh, Edinburgh, UK

    R. A. Wright, F. Stenhouse, R. A. Riemersma & N. A. Boon

  2. Scottish National Blood Transfusion Service, Headquarters Laboratory, Edinburgh, UK

    A. M. Perrie & I. R. MacGregor

  3. Department of Medicine, University of Newcastle Upon Tyne, Newcastle upon Tyne, UK

    K. G. M. M. Alberti

Authors
  1. R. A. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. Perrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Stenhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. G. M. M. Alberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. A. Riemersma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. R. MacGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. A. Boon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wright, R.A., Perrie, A.M., Stenhouse, F. et al. The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. Eur J Clin Pharmacol 46, 279–282 (1994). https://doi.org/10.1007/BF00192563

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00192563

Key words

Search

Navigation